Results 51 to 60 of about 2,401 (204)

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Beyond the Outburst: Charting a New Frontier for Understanding and Treating Irritability in Autistic Adults

Autism Research, Volume 19, Issue 7, July 2026.
ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin, Arthur N. Westover, Amy S. F. Lutz, Manish K. Jha   +3 more
wiley   +1 more source

The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders [PDF]

, 2016
Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A.
Vecchiotti R., Matarazzo I., Perna G., Iasevoli F., Garcia C. S., De Bartolomeis A., Serroni N., Prinzivalli E., De Berardis D., Valchera A., Martinotti G., Vellante F., Pompili M., Sepede G., Carano A., Di Giannantonio M., Fornaro M., Mazza M., Conti C., Orsolini L.   +19 more
core   +3 more sources

Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract The US FDA recently accepted efficacy extrapolation from adult to pediatric patients for atypical antipsychotics in the treatment of schizophrenia (SCZ) and bipolar mania (BPM), considering the similarity in both disease and exposure‐response relationships for this class of drugs.
Shams Ismaeil, Lucia Siovitz, Rahul K. Goyal, Doerthe Eckert, Sven Stodtmann, Hao Xiong   +5 more
wiley   +1 more source

Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults [PDF]

, 2020
Purpose of Review: Antipsychotics are the standard of care when it comes to the treatment of Schizophrenia, and they are often used in Bipolar as well. Their use can come with adverse effects such as extrapyramidal movements, metabolic complications as ...
Kaye, Adam M., Edinoff, Amber N, Jani, Devanshi, Ruoff, Miriam T., Cornett, Elyse M., Ghaffar, Yahya T., Viswanath, Omar, Urits, Ivan, Kaye, Alan David, Rezayev, Arthur   +9 more
core  

Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up [PDF]

, 2023
Background: Cariprazine, a novel antipsychotic drug that is a partial agonist with preferential binding to the D3 receptor, has demonstrated efficacy in clinical trials across all symptom domains, including negative symptoms, which can occur early in the
Maret, Jose, Pappa, Sofia, Kalniunas, Arturas   +2 more
core   +1 more source

A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

Frontiers in Psychiatry
Management of negative symptoms is one of the most challenging and important unmet needs of schizophrenia treatment. Negative symptoms together with positive symptoms result in significant psychosocial impairment and poor quality of life.
Panneer Selvan, Prashant Devkare, Arthik Shetty, Shruti Dharmadhikari, Chintan Khandhedia, Amey Mane, Suyog Mehta, Chittaranjan Andrade   +7 more
doaj   +1 more source

Electrochemical Hofmann Rearrangement for Modular Synthesis of Unsymmetrical Ureas and Late‐Stage Modification of Drugs

Advanced Science, Volume 13, Issue 31, 4 June 2026.
An electrochemical Hofmann rearrangement of amide involving amine or other amide nucleophiles has been developed. The use of NaI guarantees the feasibility and compatibility of the electrosynthesis protocol, which enables highly chemoselective synthesis of unsymmetrical N‐acylureas from two different amides, as well as the production of unsymmetrical ...
Xue‐Qing Mou, Xiao Zha, Yu‐Rui Jian, Shao‐Xing Zhong, Xin‐Yu Fu, Sheng‐Yang Xu, Wei Xiang, Bao‐Dong Cui, Yun Zhang, Yong‐Zheng Chen   +9 more
wiley   +1 more source

Role Of Cariprazine In Schizophrenia: A Review [PDF]

Schizophrenia is a severe mental illness and is most commonly observed/ encountered by the majority of clinicians during their clinical practice Among numerous treatment methods, Cariprazine, and its related drugs have shown their clinical efficacy in ...
Ayush Kumar, Mohit Goyal, Srishti Gosain, Sakshi Garg, Saumya Goyal, Shaffi K. Tangri   +5 more
core   +2 more sources

Cariprazine as a strategy for augmentation of treatment of major depressive disorder: from pharmacological aspects to clinical practice

Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Major depressive disorder remains the leading cause of disability worldwide, with up to 33% of patients failing to respond to antidepressant therapy.
A. V. Kidyaeva, R. F. Nasyrova
doaj   +1 more source